Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYi LiMZMing ZhaoHXHaowen Xiao

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals prognostic factors affecting progression-free survival and mortality in Chinese multiple myeloma patients.

Key Points

  • Evaluate the prognostic significance of 1q21 gain and other cytogenetic abnormalities in newly diagnosed multiple myeloma patients.
  • Retrospective analysis of NDMM patients treated from July 2013 to June 2022
  • Stratification based on interphase FISH results
  • Assessment of treatment response per IMWG criteria
  • Median follow-up duration of 47.9 months
  • Patients without 1q21+ had superior PFS compared to all other groups
  • 1q21+ with HRCA exhibited significantly worse PFS and OS
  • Median OS for patients with 1q21+ and HRCA was <40 months
  • Overall survival and progression-free survival results indicate the need for improved risk stratification

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0bahttps://doi.org/10.1182/blood-2025-2242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse‐Risk Subtype in AL Amyloidosis With Inferior Long‐Term Survival2026
  2. 2Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.2025
  3. 3Real-world poor prognostic impact of del(1p32) in newly diagnosed multiple myeloma among Asian populations2025
  4. 4Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone2025
  5. 5Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025